Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Non-rheumatic conditions · Patient guide

Pain, fatigue and finding the right care

Fibromyalgia, ME/CFS, amplified pain and related conditions: a guide for patients and families.

Olga Goodman, MD · Evidence review: 25 September 2026
Watch the short film

Five stories across fibromyalgia, ME/CFS and regional pain. English audio · 2:52.

Patient interactive stories

Pain & Fatigue

No Single Test

Two years with fibromyalgia, told from the patient’s side: pain, normal tests, a handover, medicines, and the night a new pain was new.

Free after registration

Open the story →

Reviewed

Pain & Fatigue

The Crash Arrives Late

Eighteen months of ME/CFS after a virus, told from the patient’s side: the delayed crash, the budget, the watch, the clinic abroad, and a review done right.

Free after registration

Open the story →

Reviewed

Pain & Fatigue

The Border

Four years with a spondyloarthritis you were afraid to treat and a pain syndrome that grew beside it: when pain, examination, blood tests and imaging disagree.

Free after registration

Open the story →

Reviewed

Tools and comparisons
On this page
  1. Where this guide belongs
  2. The first distinction: pain, fatigue, sleepiness or weakness?
  3. When new symptoms need urgent assessment
  4. Fibromyalgia: what the diagnosis means
  5. Fibromyalgia: a workable treatment plan
  6. Medicines for fibromyalgia
  7. When treatment has not helped
  8. ME/CFS is more than chronic tiredness
  9. PEM: the activity response that changes care
  10. Pacing and rehabilitation with PEM
  11. Treating ME/CFS symptoms and severe illness
  12. Children: AMPS and juvenile widespread pain
  13. Regional pain, CRPS and nerve pain
  14. Dizziness on standing and POTS
  15. Hypermobility, Long COVID and other overlapping conditions
  16. Experimental treatment: questions that protect a decision
  17. Devices, oxygen, supplements and peptides
  18. Preparing a useful appointment

Where this guide belongs

Fibromyalgia, ME/CFS and amplified pain syndromes can cause major disability. They are not systemic inflammatory autoimmune rheumatic diseases and need their own assessment and care plan.

Fibromyalgia, ME/CFS and amplified pain syndromes can cause major disability. They are not systemic inflammatory autoimmune rheumatic diseases and need their own assessment and care plan. They can also coexist with a rheumatic disease.

A rheumatologist may clarify whether an inflammatory rheumatic disease is present. Ongoing care should then have a named coordinator and access to the services the person needs. A change of specialty should come with a workable plan. It does not mean the symptoms are imaginary or unimportant.

The first distinction: pain, fatigue, sleepiness or weakness?

Fatigue is lack of usable energy. Sleepiness is a tendency to fall asleep.

Fatigue is lack of usable energy. Sleepiness is a tendency to fall asleep. Weakness is difficulty generating muscle force. Pain can restrict movement without true muscle weakness. These problems may coexist but lead to different investigations. Describe what happens during an ordinary day, what changed from your previous ability and what follows an activity the next day.

When new symptoms need urgent assessment

Seek urgent medical help for new chest pain, severe breathlessness, sudden one-sided weakness, loss of bladder or bowel control with new leg weakness or numbness around the groin, or a hot swollen joint with fever. Rapidly worsening weakness, inability to drink, major dehydration or suicidal thoughts also need prompt help.

Seek urgent medical help for new chest pain, severe breathlessness, sudden one-sided weakness, loss of bladder or bowel control with new leg weakness or numbness around the groin, or a hot swollen joint with fever. Rapidly worsening weakness, inability to drink, major dehydration or suicidal thoughts also need prompt help. An existing pain or fatigue diagnosis must not explain away a new emergency.

Fibromyalgia: what the diagnosis means

Fibromyalgia involves widespread pain with symptoms such as unrefreshing sleep, fatigue and difficulty thinking. A clinician uses the pattern and duration of symptoms, examination and selected tests.

Fibromyalgia involves widespread pain with symptoms such as unrefreshing sleep, fatigue and difficulty thinking. A clinician uses the pattern and duration of symptoms, examination and selected tests. No single blood test confirms it. Normal inflammatory markers do not prove it, and a positive ANA alone does not establish lupus. Fibromyalgia can coexist with arthritis or another illness.

The diagnosis does not mean that pain is invented. Altered pain processing is an important clinical model; research continues into several biological mechanisms. A research finding is not yet a routine diagnostic test for an individual.

Fibromyalgia: a workable treatment plan

Begin with a small number of goals that matter to you: better sleep, easier washing and dressing, less disruptive pain or a more predictable day. Education, individually adapted movement, sleep care and psychological pain-management skills may all help.

Begin with a small number of goals that matter to you: better sleep, easier washing and dressing, less disruptive pain or a more predictable day. Education, individually adapted movement, sleep care and psychological pain-management skills may all help. CBT or ACT can support coping and function without implying a psychological cause.

Check for post-exertional malaise before increasing activity. If it is absent, gradual, tolerable movement can be developed with your team. If activity causes delayed, prolonged worsening of several symptoms, the plan needs reassessment. Pain rehabilitation is not a competition, and a flare is information for adjusting care.

Medicines for fibromyalgia

US-approved options include duloxetine, milnacipran, pregabalin and the sublingual cyclobenzaprine product Tonmya, approved in 2025. Approvals differ by country and age; Tonmya is not interchangeable with an ordinary cyclobenzaprine tablet.

US-approved options include duloxetine, milnacipran, pregabalin and the sublingual cyclobenzaprine product Tonmya, approved in 2025. Approvals differ by country and age; Tonmya is not interchangeable with an ordinary cyclobenzaprine tablet. Some other medicines, such as amitriptyline, are used off label in selected patients.

These medicines help some people and can cause adverse effects. Discuss the target, interactions, an agreed review and a stopping plan. More medicines do not necessarily provide more benefit. Do not abruptly stop an antidepressant, pregabalin or an established opioid regimen without a plan. Steroids and immune suppressants are not routine fibromyalgia treatments. Opioid escalation is generally a poor long-term strategy for this condition.

When treatment has not helped

Review the original diagnosis, the actual trial duration, adverse effects, sleep disorders, orthostatic symptoms, mood and other pain sources. Ask whether the chosen treatment addressed your main limitation.

Review the original diagnosis, the actual trial duration, adverse effects, sleep disorders, orthostatic symptoms, mood and other pain sources. Ask whether the chosen treatment addressed your main limitation. A clinician may simplify medications rather than keep adding them. Persistent symptoms do not demonstrate lack of effort and do not, on their own, prove hidden autoimmune disease.

ME/CFS is more than chronic tiredness

Myalgic encephalomyelitis/chronic fatigue syndrome is defined by a particular pattern: substantially reduced function, post-exertional malaise, unrefreshing sleep and cognitive or orthostatic symptoms. Different diagnostic frameworks use different duration requirements.

Myalgic encephalomyelitis/chronic fatigue syndrome is defined by a particular pattern: substantially reduced function, post-exertional malaise, unrefreshing sleep and cognitive or orthostatic symptoms. Different diagnostic frameworks use different duration requirements. Chronic fatigue is also a symptom of many other conditions, so the terms must not be used as if they were interchangeable.

Assessment includes a history, examination and proportionate testing for other explanations. There is no single routine confirmatory blood test. It is possible to have both ME/CFS and fibromyalgia, or ME/CFS after COVID-19.

PEM: the activity response that changes care

Post-exertional malaise is a worsening of symptoms after physical, mental, emotional or social effort that previously would have been manageable. It may begin later, often after 12–48 hours, and last days or longer.

Post-exertional malaise is a worsening of symptoms after physical, mental, emotional or social effort that previously would have been manageable. It may begin later, often after 12–48 hours, and last days or longer. Pain, cognition, sleep and flu-like symptoms can worsen together. It differs from ordinary tiredness after activity.

Record the activity, any delay, the symptoms and the recovery time. Do not deliberately provoke a crash to prove that PEM is real. A diary can help a clinician recognize a pattern but cannot diagnose the disease by itself.

Pacing and rehabilitation with PEM

Pacing means adjusting demands and rest to stay within a sustainable energy limit. Washing, conversation, screens, travel and thinking all count.

Pacing means adjusting demands and rest to stay within a sustainable energy limit. Washing, conversation, screens, travel and thinking all count. Break tasks into smaller parts, plan rest and allow for fluctuations. A heart-rate monitor may help some people notice patterns, but no universal pulse target guarantees safety.

Fixed increases in exercise that ignore symptoms are inappropriate for ME/CFS. Any movement plan must be individualized and flexible. Pacing is a management strategy, not a proven cure; it should not become an instruction to avoid all movement regardless of ability.

Treating ME/CFS symptoms and severe illness

Care can address sleep disorders, pain, migraine, orthostatic intolerance, nutrition and other coexisting problems. Start with the symptom that most limits daily life and assess tolerability.

Care can address sleep disorders, pain, migraine, orthostatic intolerance, nutrition and other coexisting problems. Start with the symptom that most limits daily life and assess tolerability. CBT may support adaptation; it is not a cure for ME/CFS.

For people who are housebound or bedbound, access matters: shorter or remote appointments, lower light and noise, help with food and fluids, pressure-area care and a coordinated home plan. Severe decline, swallowing problems or inadequate intake require active medical assessment. Avoid unnecessary exertion during assessment and transport.

Children: AMPS and juvenile widespread pain

Amplified musculoskeletal pain syndrome describes several childhood pain presentations. Assessment looks for injury, inflammation, neurological disease and other causes.

Amplified musculoskeletal pain syndrome describes several childhood pain presentations. Assessment looks for injury, inflammation, neurological disease and other causes. Treatment commonly combines physical and occupational therapy, pain education, coping support and a supported return to daily activities and school.

Plans should be tailored to the child, with family participation and realistic educational accommodations. Delayed prolonged worsening, significant orthostatic symptoms or systemic signs require reassessment. An intensive AMPS program must not automatically be copied into a child with ME/CFS and PEM. The child is not to blame for pain.

Regional pain, CRPS and nerve pain

Local muscle or tendon pain, nerve pain and complex regional pain syndrome need their own assessment. CRPS may involve disproportionate regional pain with changes in temperature, colour, swelling, sweating or movement.

Local muscle or tendon pain, nerve pain and complex regional pain syndrome need their own assessment. CRPS may involve disproportionate regional pain with changes in temperature, colour, swelling, sweating or movement. It is not simply a severe form of fibromyalgia. Burning pain or altered sensation may suggest neuropathy, although symptoms alone cannot confirm it.

Neurology or a pain service may be appropriate. Selected nerve tests or a skin biopsy have specific indications; they are not universal tests for all widespread pain. A normal standard nerve-conduction study does not exclude small-fiber neuropathy.

Dizziness on standing and POTS

Palpitations, lightheadedness and brain fog while upright can reflect orthostatic intolerance. POTS is one possible diagnosis and requires a structured assessment, including exclusion of other causes of a fast heart rate.

Palpitations, lightheadedness and brain fog while upright can reflect orthostatic intolerance. POTS is one possible diagnosis and requires a structured assessment, including exclusion of other causes of a fast heart rate. A single smartwatch reading is insufficient.

Management may include adapted fluids, salt, compression and selected medication. These depend on blood pressure, kidney and heart health and other factors; do not apply high-salt advice universally. When PEM is present, exercise recommendations need the same care as in ME/CFS. Recurrent fainting or new chest symptoms deserve assessment.

Hypermobility, Long COVID and other overlapping conditions

Flexible joints alone do not diagnose hypermobile Ehlers–Danlos syndrome. Symptomatic hypermobility may benefit from stabilization, joint protection and individualized rehabilitation.

Flexible joints alone do not diagnose hypermobile Ehlers–Danlos syndrome. Symptomatic hypermobility may benefit from stabilization, joint protection and individualized rehabilitation. Long COVID can include fatigue, pain, cognitive problems, PEM and autonomic symptoms, but people do not all have the same illness pattern.

Sleep apnea, anemia, thyroid disease, medication effects, nutritional deficiency and neurological disease can also contribute. Functional neurological disorder is diagnosed through appropriate positive clinical signs by a trained clinician; it must not be assigned merely because tests are normal.

Experimental treatment: questions that protect a decision

Ask what was studied, in how many people, against what comparison, and whether meaningful daily function improved. Registration of a trial is not proof of success.

Ask what was studied, in how many people, against what comparison, and whether meaningful daily function improved. Registration of a trial is not proof of success. An approved drug used for another condition is not automatically approved for yours. Cost, travel, monitoring and recovery time are part of the treatment burden.

LDN has important negative randomized trials in fibromyalgia. Small studies of aripiprazole, rapamycin or daratumumab in ME/CFS are not established treatment protocols. Rituximab failed to show benefit in a major ME/CFS trial. Immune depletion, plasma exchange and infusions require particular caution and a valid indication.

Devices, oxygen, supplements and peptides

Brain stimulation and hyperbaric oxygen have clinical research signals in selected fibromyalgia groups, but protocols and lasting benefit vary. Acupuncture or other complementary methods may be considered as adjuncts with a defined goal.

Brain stimulation and hyperbaric oxygen have clinical research signals in selected fibromyalgia groups, but protocols and lasting benefit vary. Acupuncture or other complementary methods may be considered as adjuncts with a defined goal. A benefit in fibromyalgia does not demonstrate benefit in ME/CFS.

Correcting a documented deficiency is different from selling a “mitochondrial cure.” BPC-157, stem-cell or exosome products do not have established efficacy for these syndromes. Ask for human evidence for the exact product and diagnosis. Neither “natural” nor “experimental” means risk-free.

Preparing a useful appointment

Bring a short timeline, your main functional limitation, the response to activity over the next two days, a medication list with benefits and harms, and relevant previous results. Agree who coordinates care, which treatment is being tried, how benefit will be judged and what new findings would justify return to rheumatology.

Bring a short timeline, your main functional limitation, the response to activity over the next two days, a medication list with benefits and harms, and relevant previous results. Agree who coordinates care, which treatment is being tried, how benefit will be judged and what new findings would justify return to rheumatology.

The visit worksheet in this collection can help organize that conversation. It does not produce a diagnosis or a treatment recommendation. Shared goals should be feasible even when recovery is incomplete.

Sources and further reading

Show sources and further reading

Original clinical sources; publication language may differ from this guide.

  1. American College of Rheumatology · Fibromyalgia
    Professional society information
  2. Wolfe et al. · 2016 revisions to fibromyalgia diagnostic criteria
    Criteria development
  3. HAS · Fibromyalgia in adults: diagnostic process and treatment strategy, 2025
    Guideline
  4. CDC · NAM/IOM 2015 diagnostic criteria for ME/CFS
    Diagnostic framework
  5. NICE NG206 · ME/CFS diagnosis and management
    Guideline
  6. CDC · Preventing symptom worsening in ME/CFS
    Clinical information
  7. CDC · Evaluation of ME/CFS, updated April 2026
    Clinical information
  8. CDC · Clinical care for severely affected patients with ME/CFS
    Clinical information
  9. CHOP · AMPS multidisciplinary consultative clinic
    Specialist care model
  10. FDA · Tonmya approval, 15 August 2025
    Regulatory decision
  11. Cymbalta · US prescribing information
    Prescribing information
  12. FDA · Lyrica US prescribing information, 2025
    Prescribing information
  13. DailyMed · Savella prescribing information
    Prescribing information
  14. Tonmya · US prescribing information
    Prescribing information
  15. Canadian Cardiovascular Society · POTS position statement, 2020
    Consensus statement
  16. GeneReviews · Hypermobile Ehlers–Danlos syndrome
    Expert clinical reference
  17. Harden et al. · CRPS practical diagnostic and treatment guidelines, fifth edition
    Specialist guideline
  18. Geerts et al. · IVIG in painful idiopathic small-fiber neuropathy, randomized trial
    Randomized trial
  19. CDC · Long COVID clinical guidance, March 2026
    Clinical guidance
  20. Rodríguez-Freire et al. · INNOVA randomized trial, 2026
    Randomized trial
  21. Fluge et al. · Rituximab in ME/CFS randomized trial, 2019
    Randomized trial
  22. Fluge et al. · Daratumumab in ME/CFS pilot study, 2025
    Open-label pilot; correction linked by publisher
  23. Ruan et al. · Low-dose rapamycin pilot study, 2025
    Uncontrolled pilot
  24. Silva et al. · Multicentre sham-controlled rTMS trial in fibromyalgia, 2025
    Randomized trial
  25. HOTFy · Hyperbaric oxygen in fibromyalgia, 2026
    Randomized crossover trial; no sham
  26. FDA · July 2026 Pharmacy Compounding Advisory Committee materials
    Regulatory advisory materials; not an approval
  27. FDA · Regenerative medicine products, stem cells and exosomes
    Regulatory information

Olga Goodman, MD · RheumaView™

Copying without attribution prohibited. Educational content; this page is not a clinical messaging service.

Back to the patient guide

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Rheumatology